The Scientific Association for Botanical Education and Research (SABER) commended Connecticut lawmakers for passing legislation expanding the state’s psychedelic-assisted therapy pilot program, a step intended to strengthen clinical research efforts related to mental health and healthcare treatments.

The measure, advanced by the Connecticut General Assembly, updates the program’s existing framework to better align with emerging federal regulatory pathways and anticipated review processes at the U.S. Food and Drug Administration.

By refining eligibility criteria and extending the program’s operational timeline, the legislation positions Connecticut to contribute to a growing body of research focused on psychedelic-assisted therapies. The program is designed to support structured clinical evaluation while maintaining safeguards related to patient safety and institutional oversight.

SABER said the expansion reflects a research-focused approach that acknowledges the increasing number of peer-reviewed studies examining psychedelic-assisted interventions for serious mental health conditions. Programs structured within academic medical centers are intended to allow clinical investigations to occur under defined protocols and monitored conditions.

Dr. Mary Hardy, a member of SABER’s Scientific Steering Committee, described the role of controlled research settings in advancing scientific understanding.

“State-level pilot programs that are embedded within academic medical centers create an opportunity to generate high-quality clinical data under controlled conditions,” said Dr. Hardy. “When investigational therapies are studied within structured protocols that include defined dosing parameters, screening criteria, adverse event monitoring, and independent oversight, the resulting data can meaningfully inform both federal review processes and long-term public health policy. Ultimately, this is about ensuring that patients have access to safe, well-studied therapies grounded in real clinical evidence.”